The Interferons Market Is Advantageous As An Alternative To Expensive Biologics Therapy

Interferons Market Report 2021: COVID 19 Implications And Growth To 2030

Interferons Global Market Report 2021: COVID 19 Implications And Growth To 2030

The Business Research Company’s Interferons Global Market Report 2021: COVID-19 Implications And Growth to 2030

LONDON, GREATER LONDON, UK, February 16, 2021 / — New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact:

Biologics therapy is expensive and it places a substantial financial burden on the healthcare system. Increasing prevalence of diseases such as hepatitis, MS, and cancers in the world presented an opportunity to evaluate the clinical applications of biosimilars and have stimulated some of the local pharmaceutical companies to produce interferon biosimilar medications to compete (or replace) the original expensive brands. IFNs were initially investigated for their potential as antivirals. However, they are now commonly used in anti-HBV (hepatitis B virus) and anti-HCV (hepatitis C virus) therapy. The therapeutic potential of interferon biosimilars for hepatitis and cancer coupled with the ongoing studies on interferon biosimilars to have prophylactic or therapeutic effectiveness in SARS (severe acute respiratory syndrome), influenza or another virus pandemic, is contributing to the increasing adoption of interferon biosimilars over expensive biologics. Interferon drugs market trends such as these drive the market.

The global interferons market size is expected to grow from $7.46 billion in 2020 to $7.61 billion in 2021 at a compound annual growth rate (CAGR) of 2%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $8.74 billion in 2025 at a CAGR of 3.5%.

In TBRC’s interferons industry analysis report, the major players covered in the market are Roche, Merck, Bristol-Myers Squibb, Biogen Inc, Bayer AG, Zydus Cadila, Novartis AG, Pfizer Inc, Biosidus, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics, PROBIOMED, Schering-Plough Corporation, 3Sbio.

Interferons Global Market Report 2021: COVID 19 Implications And Growth to 2030 is one of a series of new reports from The Business Research Company that provides interferons market overview, forecast interferons market size and growth for the whole market, interferons market segments, and geographies, interferons market trends, interferons market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Interferons Market Report:

Here Is A List Of Similar Reports By The Business Research Company:
Drugs for Immunotherapy Global Market Report 2020-30: Covid 19 Growth And Change

Multiple Sclerosis Drugs Market Global Report 2020

Global Biologics Market – By Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), By Route Of Administration (Oral, Others (IV or IP)), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription Drugs, OTC Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2023

Interested to know more about The Business Research Company?
Read more about us at

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
Visit us on social media:

Leave a Reply

Your email address will not be published.